{"id":"spk-843","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, SPK-843 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased glucose levels in the blood. This mechanism is primarily used to treat type 2 diabetes.","oneSentence":"SPK-843 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:35:55.097Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT01125644","phase":"PHASE3","title":"Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis","status":"UNKNOWN","sponsor":"Proaparts srl","startDate":"2010-05","conditions":"Cryptococcosis or Aspergillosis Infections","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SPA-S-843"],"phase":"phase_3","status":"active","brandName":"SPK-843","genericName":"SPK-843","companyName":"Proaparts srl","companyId":"proaparts-srl","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SPK-843 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Treatment of type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}